Update on neuropsychiatric adverse events suspected to be associated with oseltamivir (Tamiflu®)

The Health Sciences Authority (HSA) would like to update healthcare professionals on the local neuropsychiatric adverse events reported which were suspected to be associated with oseltamivir (Tamiflu®). The Pharmacovigilance Branch (PVB) recently received 3 local reports describing disorientation, incoherent speech, hallucination and suicidal attempt suspected to be associated with oseltamivir. Although it is unclear if the causality of these events is directly due to oseltamivir, HSA advises healthcare professionals to be aware of these neuropsychiatric events and to advise caregivers of young patients of the potential risk of these events.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.